Generative AI is transforming the healthcare landscape by offering unprecedented opportunities for faster and more accurate diagnoses, personalized medicine, and improved patient outcomes. By interpreting incomplete data, leveraging domain-specific ontologies, and linking disparate datasets, generative AI has the potential to revolutionize healthcare research and practice.

However, deploying generative AI at scale often requires significant infrastructure and expertise. Tursio is addressing this challenge by enabling organizations to convert their domain-specific databases into generative AI machines, eliminating the need for additional infrastructure while accelerating AI adoption. This blog discusses the technological trends in clinical research from the Tursio lens.

Evolution of Clinical Trials

Clinical research has evolved significantly from its early days of observation-based medicine, with no standardized tests or ethical guidelines, to the sophisticated and regulated processes of today. The history of clinical trials can be traced back to the 18th century when James Lind’s controlled trial compared treatments for scurvy, laying the foundation for clinical experiment design.

By the 20th century, randomized controlled trials (RCTs) became the “gold standard” for minimizing bias, and double-blind studies were introduced to ensure objectivity. Ethical frameworks such as the Nuremberg Code and the Declaration of Helsinki established informed consent and safeguards for human participants. Today, clinical research continues to evolve, incorporating advanced technologies and diverse data sources, from genetic profiles to real-world evidence, while addressing new challenges through innovative solutions.

Complexity of Modern Clinical Trials

Modern clinical trials are increasingly complex due to evolving demands of personalized medicine, rising patient research costs, and the explosion of data across various sources. The new era presents several challenges that require innovative solutions but also offers immense promise.

The heart of medical trials involves the patient. Identifying these patients is no longer as simple as meeting a couple of clinical criteria. Trials now require patients with rare genetic markers or specific lifestyle profiles, which turns recruitment into a race against time. Additionally, retaining qualified participants and ensuring they adhere to protocols demands proper communication, user-friendly monitoring tools, and a trial experience that feels seamless.

These trial adjustments come with a heavy price tag. It can cost up to $2.8 billion to bring a new drug to market and can take over a decade for trials to complete. With intricate trial designs, lengthy approval processes, and post-market surveillance, efficiency becomes more important. Delays equal more expenses and the pressure to deliver treatments grows ever more intense.

Fueling these trials is also the influx of disparate data sources. Electronic Health Records (EHRs) provide great quantities of both structured and unstructured patient data, including imaging results, clinical notes, and medication records. Wearables add another layer by generating real-time, longitudinal datasets, such as heart rate, activity levels, and sleep patterns. Genetic databases contribute even more detailed insights, offering patient-specific biomarkers that can inform personalized treatment plans. Integrating these data sets into a meaningful output is a large task that is only complicated further by the sheer scale and complexity.

These intertwined challenges — prioritizing patients, managing escalating costs, and working with an overwhelming amount of data — present complexities that redefine the landscape of clinical trials. For organizations to thrive, they must now adopt new innovative technologies and solutions.

Revolutionizing Clinical Research with AI

AI, particularly generative AI, is a game changer in addressing challenges brought on by clinical research. From patient recruitment to post-trial analysis, AI is streamlining processes, uncovering new insights, and transforming how treatments are developed and delivered.

AI enables personalized medicine by evaluating genetic, environmental, and lifestyle factors to craft tailored treatment plans. It also enhances efficiency by quickly analyzing large datasets to match trial criteria, reducing recruitment timelines and costs. In drug discovery, AI accelerates the process by identifying promising candidates from vast biological datasets. Post-trial, it analyzes real-world evidence and long-term outcomes, ensuring treatments remain effective and safe.

By streamlining these processes, AI is revolutionizing clinical research, delivering faster, more precise results while improving patient care.

Empowering Healthcare with Generative AI

Generative AI can address the complexities of modern clinical trials and streamline the trial process. Specifically, here are some of the scenarios that we have seen at Tursio:

1. Simplifying Patient Identification for Trials: Hospitals face the challenge of identifying patients who meet trial inclusion criteria, impacting patient care. Pharmaceutical companies also struggle to find hospitals with the right patient pool. Tursio simplifies this by allowing natural language queries, enabling both hospitals and pharmaceutical companies to quickly identify eligible patients, improving recruitment efficiency as well as accelerating drug development.
2. Accelerating Trial Design and Post-Trial Analysis: A critical component of trial design is identifying the relevant patient population suffering from specific diseases, often categorized by ICD (International Classification of Diseases) codes. Mapping ICD codes to trial criteria is essential for targeting the right participants, but it can be extremely labor-intensive and error prone. Tursio can automate this by processing complex data schemas and creating domain-specific models. This ensures that patient conditions are accurately aligned with trial requirements, optimizing participant selection, and reducing the risk of human error. With Tursio, medical practitioners can gain relevant insights in under three seconds, enabling faster trial design and seamless evaluation of long-term outcomes post-trial.
3. Generating Patient Predictions: Improving patient outcomes requires tracking and predicting clinical behavior based on patterns in similar cohorts, such as identifying patients likely to develop diabetes, hypertension, or other conditions. Manually exploring such cohorts is complex and time-consuming. Tursio simplifies this for non-experts by allowing natural language queries, automating analysis, and providing actionable insights. It auto-detects anomalies and enables real-time alerts for early intervention.

Conclusion

Generative AI is revolutionizing clinical research by addressing the complexities of modern trials, such as data integration, personalized medicine, and regulatory compliance. By leveraging AI to analyze vast datasets, predict outcomes, and streamline patient recruitment, healthcare organizations can accelerate drug discovery and improve patient care. This shift promises faster, more effective trials while maintaining ethical and regulatory standards.

Tursio is pioneering a radical novel approach of turning domain-specific databases into generative AI machines without additional infrastructure. By simplifying patient identification, integrating disparate data sources, and enabling real-time monitoring, Tursio can make clinical trial processes more efficient and personalized. With its innovative approach, Tursio is empowering researchers and physicians to leverage state-of-the-art AI technology to innovate and deliver state-of-the-art medical care.

If you are interested, please contact us here.

References

1. Reddy, S. Generative AI in healthcare: an implementation science informed translational path on application, integration, and governance. Implementation Sci 19, 27 (2024). https://doi.org/10.1186/s13012-024-01357-9
2. Bhatt A. (2010). Evolution of clinical research: a history before and beyond James Lind. Perspectives in clinical research, 1(1), 6–10.
3. Thati, S. (2024, March 11). Precision medicine in clinical trials: A statistical perspective. American Pharmaceutical Review. https://www.americanpharmaceuticalreview.com/Featured-Articles/ 611945-Precision-Medicine-in-Clinical-Trials-A-Statistical-Perspective/
4. Hart, Inc. (2024, October 15). Top challenges in Healthcare Data Management Today. Hart. https://hart.com/blog/top-challenges-in-healthcare-data-management-today
5. Chopra, H., Annu, Shin, D. K., Munjal, K., Priyanka, Dhama, K., & Emran, T. B. (2023). Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs. International journal of surgery (London, England), 109(12), 4211–4220. https://doi.org/10.1097/JS9.0000000000000705
6. Wouters, O. J., McKee, M., & Luyten, J. (2020). Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA, 323(9), 844–853. https://doi.org/10.1001/jama.2020.1166